Rodney Dawson

Uppsala University — Sweden

Medicine · Health Sciences

47h-index7.0kcitations138works8.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Tuberculosis Research and Epidemiology(98), Mycobacterium research and diagnosis(33), Pneumocystis jirovecii pneumonia detection and treatment(29), Pneumonia and Respiratory Infections(26), Diagnosis and treatment of tuberculosis(20)

Publications134 total

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
Journal of Antimicrobial Chemotherapy·2025· 2 citedOpen Access
Author Correction: Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Nature Communications·2025Open Access
Virology Outcomes of Tenofovir-lamivudine-dolutegravir in Treatment-naïve and Virologically Suppressed Individuals Switching From an NNRTI-based Regimen: An Observational Analysis at 13 Sites
Open Forum Infectious Diseases·2025· 1 citedOpen Access
Population pharmacokinetics and exposure–response relationship of the antituberculosis drug BTZ-043
Journal of Antimicrobial Chemotherapy·2025· 3 citedOpen Access
Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes
Emerging infectious diseases·2025· 1 citedOpen Access
Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis
Pharmacogenetics and Genomics·2025· 1 citedOpen Access
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
The Lancet Microbe·2025· 16 citedOpen Access
Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial
The Lancet Infectious Diseases·2024· 8 citedOpen Access
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Nature Communications·2024· 21 citedOpen Access
PET/CT guided tuberculosis treatment shortening: a randomized trial
2024· 9 citedOpen Access
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
The Lancet Infectious Diseases·2024· 48 citedOpen Access
Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries
Clinical Infectious Diseases·2024· 4 citedOpen Access
Twice-Daily Dolutegravir–Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention
Clinical Infectious Diseases·2024· 5 citedOpen Access
Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized Trial
The Journal of Infectious Diseases·2024· 10 cited
Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis
Clinical Infectious Diseases·2024· 6 citedOpen Access
Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy
Trials·2024· 9 citedOpen Access
Efficacy and Safety of 4-Months Rifapentine-Moxifloxacin Treatment of Tuberculosis in Patients with Diabetes
SSRN Electronic Journal·2024Open Access
Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials
The Lancet Microbe·2023· 10 citedOpen Access
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis
Antimicrobial Agents and Chemotherapy·2023· 13 citedOpen Access
1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis
Clinical Infectious Diseases·2023· 7 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Andreas H. Diacon(26), Stephen H. Gillespie(17), Amour Venter(16), Keertan Dheda(16), Martin J. Boeree(13), Michael Höelscher(11), Patrick Phillips(10), Richard N. van Zyl-Smit(10), Peter R. Donald(9), Norbert Heinrich(9), Rob E. Aarnoutse(9), Carl M. Mendel(8), Melvin Spigelman(8), Kim Narunsky(8), Timothy D. McHugh(7), Christo van Niekerk(6), Daniel E. Everitt(6), Grant Theron(6), Jonny Peter(6), Richard Meldau(6)